HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

The Trump administration’s latest decisions on federal health agencies, summarized and explained

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It’s the

January 28, 2025

Why a leading bird flu expert isn’t convinced that the risk H5N1 poses to people has declined

News that H5N1 avian influenza has breached another mammalian species — this time dairy cows — has taken the flu science community aback. Though cows

April 5, 2024

J&J cements footprint in Italy with €580M in investments over the next 5 years

Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, is earmarking €580 million ($622 million) in investments in Italy over the next five years

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.